| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(7 years from now) | |
Pifeltro is owned by Msd Merck Co.
Pifeltro contains Doravirine.
Pifeltro has a total of 1 drug patent out of which 0 drug patents have expired.
Pifeltro was authorised for market use on 30 August, 2018.
Pifeltro is available in tablet;oral dosage forms.
Pifeltro can be used as for use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed.
Drug patent challenges can be filed against Pifeltro from 30 August, 2022.
The generics of Pifeltro are possible to be released after 07 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 27, 2025 |
| New Indication(I-827) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
Drugs and Companies using
DORAVIRINE ingredient
NCE-1 date:
30 August, 2022
Market Authorisation Date:
30 August, 2018Treatment:
For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...Dosage:
TABLET;ORAL
More Information on Dosage
PIFELTRO family patents
